Skip to content
Search

Latest Stories

UK’s SFO drop investigations on Rolls-Royce, GSK

BRITAIN'S Serious Fraud Office (SFO) today (22) dropped major investigations into engineering firm Rolls-Royce and pharmaceutical giant GlaxoSmithKline (GSK).

Rolls Royce had already reached a £500 million agreement with the SFO over claims that corruption and bribery were used to win business in China, India, Indonesia, Thailand, Russia, Nigeria and Malaysia.


The SFO said it had now concluded that there would be "no prosecution of individuals associated with the company".

The investigation into GlaxoSmithKline related to commercial practices by the firm, its subsidiaries and associated individuals.

"After an extensive and careful examination I have concluded that there is either insufficient evidence to provide a realistic prospect of conviction or it is not in the public interest to bring a prosecution in these cases," said SFO director Lisa Osofsky. 

"In the Rolls-Royce case, the SFO investigation led to the company taking responsibility for corrupt conduct spanning three decades, seven jurisdictions and three businesses, for which it paid a fine of £497.25m."

This figure, agreed in January 2017 as part of a so-called deferred prosecution agreement, comprised surrendered profits of £258m and a financial penalty of £239m.

Rolls-Royce is also paying an estimated £13m to cover the SFO's costs.

The firm said it would not be commenting on today’s decision, beyond saying it was cooperating fully with the authorities following the 2017 deal.

In a statement, businessmen Sudhir Choudhrie and his son Bhanu Choudhrie said: "We are delighted to have been informed that the Serious Fraud Office has dropped its investigation into Rolls Royce and any individuals connected to it.

"We have always maintained our innocence and today's announcement vindicates us.

"For five long years we have had this hanging over us and it has had a huge impact on us, on our families and on our business interests.

"We now look forward to getting on with the rest of our lives with our reputations intact".

(AFP)

More For You

Anil Agarwal

Vedanta Resources, which is based in the UK and owned by Indian billionaire Anil Agarwal, has been working on reducing its debt. (Photo credit: Getty Images)

Getty Images

Anil Agarwal’s Vedanta Resources signs £438 million refinancing deal

VEDANTA LTD said on Thursday that its parent company, Vedanta Resources, has signed a loan facility agreement worth up to £438 million with international banks to refinance existing debt.

The refinancing move, where old loans are replaced by new ones, often at better terms like lower interest rates, has led ratings agencies such as S&P Global Ratings and Moody's to upgrade their outlook on the company this year.

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less
Grant Thornton's Anuj Chande urges UK firms to tap booming India

Anuj Chande

Grant Thornton's Anuj Chande urges UK firms to tap booming India

INDIAN companies are well placed to support the UK’s economic growth, Eastern Eye has been told by Anuj Chande, partner and head of the South Asia Business Group at Grant Thornton.

He was speaking after the publication of Grant Thornton’s India Meets Britain Tracker 2025: The latest trends in Indian investment in the UK, which was released last week. While companies in India need little encouragement to enter the UK market, the reverse is not true.

Keep ReadingShow less